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Case Report
We present a 58-year-old woman with a history of poorly differ-
entiated papillary thyroid carcinoma (PTC) that showed elevation 
of serum thyroglobulin (Tg) levels during routine follow up. She 
had also undergone neck dissections for three times in the last 
two years and treated with 5550 MBq 131I. The recent ultrasonog-
raphy showed suspicious metastatic lymph nodes and diagnostic 
131I-SPECT/CT revealed moderate cervical uptake which was in-
terpreted as residual lymph node metastases as well as multiple 
pulmonary nodules without 131I uptake. She experienced vertigo 
and headache during radioiodine treatment planning for lymph 
node metastases. Brain CT scan and neurosurgery consult 
was consistent with a suspicious brain mass with invasion to the 
bony structures of the skull base and due to patient history and 
her possible mass location; she was suitable for neither tissue 
sampling nor surgical intervention. Brain MRI with and without 
contrast was performed and no clear abnormality was reported.
We decided to perform 99m Tc-Octreotide scintigraphy to de-
termine the patient’s somatostatin receptor status and see if the 
patient is a good candidate for 177Lutetium-DOTATATE therapy. 
The whole-body octreotide scan was performed four hours af-
ter IV administration of 740 MBq (20 mCi) of 99m Tc-Octreotide, 
using a dual-head gamma camera equipped with low-energy, 
high-resolution collimator. Also, brain SPECT, with 128 × 128 ma-
trices and 64 projections over 3600 with 20 seconds per step, 
was performed and reconstructed using an iterative method 
(OSEM, number of iterations 8, subsets 4). Whole-body octreotide 
scan revealed multiple zones of avid lesions in the right side of 
the brain, both sides of the neck, upper mediastinum and the 
right lung (Fig. 1) which brain lesion was confirmed in the skull 
SPECT images (Fig. 2). Retrospectively, brain MRI images were 
reviewed and an abnormal focal lesion with low signal T1 and 
high signal T2 sections was at the level of the medulla and 
spinal cord junction in the right side which was confirmed in the 
Figure 1. Whole-body octreotide scan revealed multiple zones of 
octreotide avid lesions in the right side of the brain, both sides of the 
neck, upper mediastinum and the right lung
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reconstructed fused SPECT/MRI images (Fig. 3). As the skull 
bone metastasis showed acceptable uptake in 99m Tc-Octreotide 
scintigraphy, the patient became a good candidate for Peptide 
receptor radionuclide therapy (PRRNT).
Discussion
Brain metastases of PTC are rare and occur in 0.1–5% of 
this population, especially in the poorly differentiated types [1]. 
Poorly differentiated thyroid carcinoma (DTC) variants usu-
ally fail to concentrate iodine [2–5], therefore accompanied by 
negative iodine scan [6]. Presence of somatostatin analogue 
receptors is seen on the thyroid follicular cells of the majority of 
DTC patients that show elevated serum Tg levels [7–8]. Our case 
indicates that 99m Tc-Octreotide scintigraphy could be a valuable 
method in the selection of cases for radionuclide therapy (PRRNT) 
with radiolabeled somatostatin analogs. 
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Figure 3. Fused SPECT/MRI images confirmed the abnormal lesion in the right side of the skull base in the junction of the medulla and spinal cord
Figure 2. The skull SPECT image confirmed the brain lesion in the right side of the skull base
